-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases

Reuters·03/27/2026 12:15:16

Please log in to view news